EU/3/17/1905 - orphan designation for treatment of tuberculosis

Purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI
OrphanHuman

Overview

On 23 August 2017, orphan designation (EU/3/17/1905) was granted by the European Commission to Archivel Farma S.L., Spain, for purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI for the treatment of tuberculosis.

Tuberculosis (TB) is an infectious disease caused by bacteria called Mycobacterium tuberculosis. People become infected by inhaling infected droplets from the cough or sneeze of people who have the disease. TB primarily affects the lungs (called pulmonary TB) but it can also spread to other parts of the body, such as the bones or the nervous system. The symptoms of TB include persistent cough, fever, weight loss and night sweats. Not every person infected will develop the symptoms of the disease.

TB is a long-term debilitating disease that may be life threatening, mainly because of the severe damage to the lungs that does not allow the patient to breathe normally, and because the bacteria causing the disease are often resistant to existing treatments.

At the time of designation, tuberculosis affected approximately 1.6 in 10,000 people in the European Union (EU). This was equivalent to a total of around 83,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).


* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 515,700,000 (Eurostat 2017).

At the time of designation, several antibiotics were authorised in the EU to treat TB. These were used in combination and for long periods of time, normally at least six months.

The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with tuberculosis because preliminary results suggest it can be used with an existing antibiotic to increase its effectiveness. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

This medicine is a vaccine that contains substances from the cell walls of tuberculosis bacteria that have been killed and broken up. When the medicine is injected into the body, the immune system (the body's natural defences) recognises the substances in the cell wall as foreign. This stimulates the immune system to attack the same substances in living bacteria. In patients with TB, this helps to kill the bacteria and prevent symptoms of the disease from developing.

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with this medicine in patients with TB were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for TB or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 13 July 2017 recommending the granting of this designation.

  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

Active substance
Purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI
Medicine name
-
Intended use
Treatment of tuberculosis
Orphan designation status
Positive
EU designation number
EU/3/17/1905
Date of designation
Sponsor

Archivel Farma S.L.
C/ Fogars de Tordera, 61
08916 Badalona
Barcelona
Spain
Tel. +34 934 972 456
E-mail: archivel@archivelfarma.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page